W
W
N
N
G
G
S
S
C
C
H
H
V
V
N
N
C
C
A
A
S
S
G
G
G
G
P
P
S
S
A
A
T
T
Y
Y
A
A
C
C
V
V
V
V
A
A
G
G
Platform
Platform
Platform
Next-generation, natural product therapeutics have the potential to revolutionize medicine.
Next-generation, natural product therapeutics have the potential to revolutionize medicine.
Next-generation, natural product therapeutics have the potential to revolutionize medicine.
Natural Products
Natural Products
Natural Products
Interface Bio has solved the largest bottlenecks in natural product discovery
Commensal microbes have coevolved with humans for millions of years, giving rise to a massive repertoire of non-toxic, bioactive, and multi-mechanism molecules. By combining precision culturomics, targeted metabolomics, molecular engineering, and AI, Interface Bio’s platform mines these natural product libraries to develop next generation, multi-mechanism therapeutics.
Advanced Therapeutics
Our lead asset is a sactipeptide, a new class of peptide therapeutics.
Sactipeptides are a unique subclass of peptide therapeutics that leverage the potency of antibodies with the size of small molecules. Three key features set them apart:
01
Unique Thioether Bridges
Unique bridges provide extreme strength over any other peptide class
02
Co-evolution with Humans
03
Large Loop Regions
Advanced Therapeutics
Our lead asset is a sactipeptide, a new class of peptide therapeutics.
Sactipeptides are a unique subclass of peptide therapeutics that leverage the potency of antibodies with the size of small molecules. Three key features set them apart:
01
Unique Thioether Bridges
Unique bridges provide extreme strength over any other peptide class
02
Co-evolution with Humans
03
Large Loop Regions
Advanced Therapeutics
Our lead asset is a sactipeptide, a new class of peptide therapeutics.
Sactipeptides are a unique subclass of peptide therapeutics that leverage the potency of antibodies with the size of small molecules. Three key features set them apart:
01
Unique Thioether Bridges
Unique bridges provide extreme strength over any other peptide class
02
Co-evolution with Humans
03
Large Loop Regions
World Leaders
World Leaders
World Leaders
Interface Bio has developed the world’s first sactipeptide therapeutic
Our platform makes us the only lab with access to this unique class of molecules. Using our AI-enabled, peptide-based drug discovery platform, we generate and optimize sactipeptide molecules to develop life changing therapeutics for complex diseases.
Our CausalVision Platform
Our CausalVision Platform
Our CausalVision Platform
Leveraging machine learning to discover and develop next-generation immunotherapies
Our platform technology makes the discovery and development of our lead asset a repeatable process by mining for more best-in-class immunotherapies.
01
Build
Proprietary AI algorithms identify high-value natural products to produce in-house.
Commensal derived natural products are an extremely difficult-to-study class of molecules. We use our proprietary AI modeling systems to search through human commensal sequencing and metabolomic data to identify molecules predicted to have drug-like properties (stable, high-yield, bioactive). We are the only lab in the world with the technology to produce sactipeptides in compliance with GMP standards.
01
Build
Proprietary AI algorithms identify high-value natural products to produce in-house.
Commensal derived natural products are an extremely difficult-to-study class of molecules. We use our proprietary AI modeling systems to search through human commensal sequencing and metabolomic data to identify molecules predicted to have drug-like properties (stable, high-yield, bioactive). We are the only lab in the world with the technology to produce sactipeptides in compliance with GMP standards.
01
Build
Proprietary AI algorithms identify high-value natural products to produce in-house.
Commensal derived natural products are an extremely difficult-to-study class of molecules. We use our proprietary AI modeling systems to search through human commensal sequencing and metabolomic data to identify molecules predicted to have drug-like properties (stable, high-yield, bioactive). We are the only lab in the world with the technology to produce sactipeptides in compliance with GMP standards.
01
Build
Proprietary AI algorithms identify high-value natural products to produce in-house.
Commensal derived natural products are an extremely difficult-to-study class of molecules. We use our proprietary AI modeling systems to search through human commensal sequencing and metabolomic data to identify molecules predicted to have drug-like properties (stable, high-yield, bioactive). We are the only lab in the world with the technology to produce sactipeptides in compliance with GMP standards.
02
Screen
Phenotypic and target driven screens identify therapeutic candidates
After production of our high-value natural product libraries, we use a combination of phenotypic and target-based screens to identify assets with high potency against previously intractable targets.
02
Screen
Phenotypic and target driven screens identify therapeutic candidates
After production of our high-value natural product libraries, we use a combination of phenotypic and target-based screens to identify assets with high potency against previously intractable targets.
02
Screen
Phenotypic and target driven screens identify therapeutic candidates
After production of our high-value natural product libraries, we use a combination of phenotypic and target-based screens to identify assets with high potency against previously intractable targets.
02
Screen
Phenotypic and target driven screens identify therapeutic candidates
After production of our high-value natural product libraries, we use a combination of phenotypic and target-based screens to identify assets with high potency against previously intractable targets.
03
Optimize
We engineer the structures for optimal potency and stability
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
03
Optimize
We engineer the structures for optimal potency and stability
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
03
Optimize
We engineer the structures for optimal potency and stability
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
03
Optimize
We engineer the structures for optimal potency and stability
Once the hit-to-leads are identified via immune screens, we use a combination of AI and rational engineering to design the optimal sequence, structure, and composition of our drug candidate
04
Validate
Our asset's bioactivity, drug stability, safety, and disease efficacy is validated.
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
04
Validate
Our asset's bioactivity, drug stability, safety, and disease efficacy is validated.
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
04
Validate
Our asset's bioactivity, drug stability, safety, and disease efficacy is validated.
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
04
Validate
Our asset's bioactivity, drug stability, safety, and disease efficacy is validated.
All assets are vetted for translation in extensive in vitro, ex vivo, and in vivo modeling systems. Hits that are identified and optimized through the platform are validated for translation to the clinic with a specific focus on mechanism and patient need.
Discover how we are using our platform for Drug Discovery
Explore our drug pipeline and see how we are using are expertise for next generation therapeutics.